Parasite clearance after malaria therapy: staying a step ahead of drug resistance

BMC Medicine

Harin A. Karunajeewa¹ 

[1] Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville 3052, Vic, Australia

关键词: Parasite clearance;    Malaria;    Falciparum;    Artemisinin combination therapy;    Antimalarial;   

Others  :  1228311
DOI  :  10.1186/s12916-015-0486-1

 received in 2015-09-11, accepted in 2015-09-11,  发布年份 2015

【 摘 要 】

The discovery and development of the artemisinin class of antimalarial drugs is one of the great recent success stories of global health. However, after at least two decades of successful use, resistance has finally emerged and appears to be spreading rapidly throughout South-East Asia in spite of our best efforts at containment. If this were also to occur in Africa, it would have disastrous implications for the continent subject to the world’s greatest burden of Plasmodium falciparum. The earliest indications of incipient artemisinin resistance may be a slowing of the rate at which parasites are cleared from the blood following treatment. The Worldwide Antimalarial Resistance Network have analysed data from 29,493 patients from 84 clinical trials in order to define the nature and determinants of early parasite clearance following artemisinin-based treatment in African populations. In doing so, they lay the foundation for systems intended to enable the earliest possible detection of emerging artemisinin resistance in Africa.

Please see related article: http://www.biomedcentral.com/1741-7015/13/212

【 授权许可】

   
2015 Karunajeewa.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]World Health Organization. World Malaria Report 2014. Geneva: WHO; 2014. http://www. who.int/malaria/publications/world_malaria_report_2014/en/ webcite
• [2]Karunajeewa HK. Artemisinins: artemisinin, dihydroartemisinin, artemether and artesunate. In: Treatment and prevention of malaria antimalarial drug chemistry, action and use, vol. 1. 1st ed. Staines H, Krishna S, editors. Springer, Basel; 2012: p.157-80.
• [3]White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW et al.. Averting a malaria disaster. Lancet. 1999; 353:1965-7.
• [4]World Health Organization. Guidelines for the treatment of malaria. Third edition. Geneva: WHO; 2015. http://www. who.int/malaria/publications/atoz/9789241549127/en/ webcite
• [5]Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F et al.. A research agenda to underpin malaria eradication. PLoS Med. 2011; 8: Article ID e1000406
• [6]Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S et al.. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014; 371:411-23.
• [7]Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008; 359:2619-20.
• [8]Chaorattanakawee S, Saunders DL, Sea D, Chanarat N, Yingyuen K, Sundrakes S et al.. Ex vivo drug susceptibility testing and molecular profiling of clinical plasmodium falciparum isolates from Cambodia from 2008 to 2013 suggest emerging piperaquine resistance. Antimicrob Agents Chemother. 2015; 59:4631-43.
• [9]Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R et al.. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis. 2015; 15:683-91.
• [10]Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S et al.. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect Dis. 2013; 13:1043-9.
• [11]Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N et al.. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014; 505:50-5.
• [12]Flegg JA, Guerin PJ, White NJ, Stepniewska K. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J. 2011; 10:339. BioMed Central Full Text
• [13]White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother. 1997; 41:1413-22.
• [14]World Health Organization. Methods for surveillance of antimalarial drug efficacy. Geneva: WHO; 2009. http://www. who.int/malaria/publications/atoz/9789241597531/en/ webcite
• [15]WWARN Artemisinin based Combination Therapy (ACT) Africa Baseline Study Group. Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated malaria: a meta-analysis of individual patient data. BMC Med. 2015;13:212.
• [16]Hastings IM, Kay K, Hodel EM. How robust are malaria parasite clearance rates as indicators of drug effectiveness and resistance? Antimicrob Agents Chemother. 2015. Ahead of print.